Rapidly progressive dementia covers many conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' new evaluations help identify the cause of rapidly progressive dementia, to guide prognosis and treatment decisions.
Show notesSpeaker 3: (
00:32)
Can you provide a little background about your role here at Mayo Clinic and experience with this disease state?
Speaker 3: (
01:21)
Can you give us an understanding of rapidly progressive dementia? How is it different and what should physicians be looking for?
Speaker 3: (
03:13)
You mentioned "syndromic" and that there are several diseases underneath that, one of them being Creutzfeldt-Jacob. Can you explain the others in a bit more detail? What makes them each unique under the heading of rapidly progressive dementias?
Speaker 3: (
05:29)
Does that encompass it: prion diseases, then the neurodegenerative bucket, then autoimmune?
Speaker 3: (
06:03)
Can you speak to the components of the new Creutzfeldt-Jacob disease-specific evaluation and the rapidly progressive dementia evaluation, and the assays that they're performed on?
Speaker 3: (
09:30)
Anything you want to add to that summary of the assays' components?
Speaker 3: (
11:09)
Can you explain the role — or lack thereof — of the 14-3-3 protein biomarker, according to our research?
Speaker 3: (
13:44)
Which patients should get this testing, and who should not?
Speaker 3: (
17:22)
What does it mean if the results come back positive and if the results come back negative?
Speaker 3: (
21:57)
What are you most excited about with these tests?